Key facts
as of Sep 2026- It has raised $244.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($90.0M) in Jun 2024.
- Notable investors include Fidelity Management & Research Company, RA Capital Management, KB Investment, Alexandria Venture Investments, BlackRock — 12 tracked in total.
- 2 institutional filers report fund marks on Bright Peak Therapeutics across 30 filings.
- Bright Peak Therapeutics has filed 2 Form Ds with the SEC since 2021, most recently Jun 2024 ($90.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Bright Peak Therapeutics
Recorded secondary trades
No secondary trades in Bright Peak Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 30 fair-value marks on Bright Peak Therapeutics between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout Bright Peak Therapeutics
Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops immuno-cytokines with pharmacological properties that allow tissue and cell-specific targeting through cytokine payload with the added potential for enhanced efficacy, enabling doctors to improve treatment outcomes and quality of life for patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Allschwil, Switzerland
- Founded
- 2017
- Employees
- 57
- Website
- brightpeaktx.com/
- Ownership
- Privately Held (backing)